Článek uvádí doporučení, jak hodnotit riziko léčiv užívaných matkou pro její kojené dítě. Možné riziko určitého množství léčiva, obsaženého v mateřském mléce, je vždy třeba porovnávat s přínosy kojení. Vzhledem k tomu, že kojení má velký význam nejen pro zdraví, správný růst a vývoj dítěte, ale také pro zdraví matky, nemělo by být nikdy doporučeno jeho předčasné ukončení kvůli léčbě matky, aniž by byly stanoveny závažné důvody. Při posuzování možného rizika je třeba prostudovat co nejvíce údajů o přestupu léčiva do mateřského mléka, o farmakokinetice daného léčiva v organismu dítěte a o jeho doložených či potenciálních nežádoucích účincích u kojených dětí. Rovněž je třeba posoudit celkový zdravotní stav konkrétního dítěte.
The article aims at recommendations how to assess the risk of drugs, taken by the mother, to her breastfed child. Some amount of drug present in breast milk always carries possible risks for an infant, however, these risks should be weight to benefits of breastfeeding itself. Breastfeeding offers big advantages for health state, healthy growth and development of the child, but also for the health of the mother. Therefore, it should not be prematurely terminated due to mother´s therapy without any concrete serious reason. During the assessment of possible risks for the infant it is necessary to study all available data on the transfer of the drug into breast milk, on pharmacokinetics in the infant and on the documented or suspected adverse reactions in breastfed infants. The general health state of the infant should be taken into consideration as well. The basic source of information is the Summary of Product Information for the concrete medicinal product which contains well documented and approved data. However, for majority of medicinal products there is not enough of well-documented data on drug use during breastfeeding. Therefore, any further data should be searched in scientific literature. A physician who prescribes a medicine to a breastfeeding woman should always explain her all the possible risks and instruct her on the possible manifestation of adverse reactions and on the need to consult in time a paediatrician. During the treatment of the mother the physician should be with her in close contact and should carefully follow conditions of the breastfed child.
- MeSH
- Abortifacient Agents, Nonsteroidal pharmacology MeSH
- Abortifacient Agents, Steroidal pharmacology MeSH
- Safety MeSH
- Angiotensin II Type 1 Receptor Blockers pharmacology MeSH
- Drug Evaluation MeSH
- Hypnotics and Sedatives * pharmacology MeSH
- Abortion, Induced * MeSH
- Angiotensin-Converting Enzyme Inhibitors pharmacology MeSH
- Drug Therapy, Combination * MeSH
- Humans MeSH
- Sleep Initiation and Maintenance Disorders drug therapy MeSH
- Pyridines therapeutic use MeSH
- Renin-Angiotensin System * drug effects MeSH
- Renin antagonists & inhibitors MeSH
- Practice Guidelines as Topic MeSH
- Adverse Drug Reaction Reporting Systems * MeSH
- Check Tag
- Humans MeSH
